This message contains images. If you don't see images, click here to view.
  Mobile version   RSS   Subscribe   Unsubscribe
Home   Membership   Events   Resources   Accreditation April 14, 2010
Curing childhood cancer carries a price later in life
NPR    Share   Share on FacebookTwitterShare on LinkedinE-mail article
Perhaps the greatest victory in cancer treatment is the success doctors have had with children. Four of five children and teenagers who get cancer can expect to be alive and well five years later. That's the usual definition of a cancer cure. But this happy story has a darker side. A analysis just published in the Annals of Internal Medicine predicts survivors of childhood cancers will live from four to 18 fewer years than people their age who haven't battled cancer. More

Blocking gene boosts cancer-killing radiotherapy
BBC News    Share    Share on FacebookTwitterShare on LinkedinE-mail article
A gene that hinders the ability of radiotherapy to kill cancer cells has been detected by UK researchers. The team found that if they blocked the POLQ gene, which has a role in repairing damaged DNA, radiotherapy was more effective. It is hoped that the discovery, which came about after a trawl through 200 candidate genes, could lead to new drugs to boost radiotherapy. The findings are published in the journal Cancer Research. More

Cancer drug safe for late-stage pelvic disease
HealthDay News via BusinessWeek    Share    Share on FacebookTwitterShare on LinkedinE-mail article
It's safe to use a new oral anti-cancer drug called vorinostat with short-term palliative radiation therapy in patients with advanced pelvic cancer, according to a phase 1 study. Palliative therapy is used to help control symptoms in patients who can't be cured. Radiation therapy is an effective palliative treatment to control pain and bleeding in patients with advanced pelvic cancer who aren't eligible for curative radiation therapy or surgery. Vorinostat, a type of histone deacetylase inhibitor, is believed to stop tumor growth by altering the expression of several genes necessary for cancer growth. More

FDA toughens process for radiation equipment
The New York Times    Share    Share on FacebookTwitterShare on LinkedinE-mail article
The Food and Drug Administration said April 8 that it was taking steps to reduce overdoses, underdoses and other errors in radiation therapy by strengthening the agency's approval process for new radiotherapy equipment. In a letter to manufacturers, the FDA said its action was based on a recent analysis of more than 1,000 reports of errors involving these devices that were filed during the last 10 years. More

Drug combination shows benefit in biliary tract cancer
Health Day News via ModernMedicine    Share    Share on FacebookTwitterShare on LinkedinE-mail article
In patients with advanced biliary tract cancer, cisplatin plus gemcitabine is linked to a survival advantage compared to gemcitabine alone, with no additional substantial toxicity, according to research published in the April 8 issue of the New England Journal of Medicine. Dr. Juan Valle of Christie Hospital in Manchester, U.K., and colleagues analyzed data from 410 patients with locally advanced or metastatic cholangiocarcinoma, gallbladder cancer, or ampullary cancer who were randomized to receive cisplatin followed by gemcitabine or gemcitabine alone. More

More trials, better data needed for breast cancer in men
HemOnc Today    Share    Share on FacebookTwitterShare on LinkedinE-mail article
Breast cancer consortia in the United States and Europe have pledged to work together to improve clinical trials and access epidemiological data and develop treatment options for men with breast cancer. Male breast cancer makes up less than 1 percent of all cancer diagnoses worldwide, and almost all data on the disease come from small single-institution studies. More

Prostate cancer-specific mortality and the extent of therapy in healthy elderly men with high-risk prostate cancer
UroToday    Share    Share on FacebookTwitterShare on LinkedinE-mail article
The risk of prostate cancer-specific mortality in healthy elderly men may depend on extent of treatment. The authors of this report compared the use of brachytherapy alone with combined brachytherapy, external-beam radiation to the prostate and seminal vesicles, and androgen-suppression therapy in this population. More

Radiation Oncology Consulting
Churchill Consulting, Inc., providing expert products and services since 1992. Premier product is DIRECTREES® (coding help application). Services include comprehensive chart audits, coding seminars, compliance programs, and QA Programs. MORE

Gum disease linked to head, neck cancer
Reuters    Share    Share on FacebookTwitterShare on LinkedinE-mail article
The health hazards associated with chronic periodontitis extend way beyond the mouth. For years people have been warned that persistent periodontitis can cause heart disease. Now a new study suggests that gum disease also may be a risk factor for cancers of the head and neck. As reported in the journal Cancer Epidemiology, Biomarkers, and Prevention, the study included 266 patients with cancers of the head or neck treated between 1999 and 2005, and 207 control subjects. More

Pairing up against cancer
RSC Publishing    Share    Share on FacebookTwitterShare on LinkedinE-mail article
Researchers from the University of Bath and their collaborators have demonstrated a novel approach to anticancer drug design that combines the active fragments of two known anticancer agents that work in different ways to kill cancer cells. In doing so, Barry Potter and his team have discovered a new family of compounds that could be more effective than either of the parent molecules while also overcoming many of their drawbacks. More

Mouth health: Tobacco use, alcohol, oral cancer
The Huffington Post    Share    Share on FacebookTwitterShare on LinkedinE-mail article
More than 35,000 Americans will be diagnosed with oral cancer this year. Most of them will be tobacco users of some kind: smokers, former smokers and smokeless tobacco users. There is no nice way to paint the picture, so I'll just start swinging away with my brush -- of people 50 years of age or older and diagnosed with oral cancer, more than 75 percent of them are/were tobacco users. And some studies I've seen that include throat and larynx cancers put the number closer to 90 percent. More
RadOnc Weekly
Ben Maitland, Director of Advertising Sales, 972.402.7025   Download media kit
Patrick McCoy, Content Editor, 469.420.2603   Contribute news
This edition of RadOnc Weekly was sent to ##Email##. To unsubscribe, click here. Did someone forward this edition to you? Subscribe here -- it's free!
Recent issues
April 7, 2010
March 31, 2010
March 24, 2010
March 17, 2010

7701 Las Colinas Ridge, Ste. 800, Irving, TX 75063